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AbstrAct
Objective To evaluate the relationship between disease 
activity and radiographic progression in rheumatoid 
arthritis, three phase iii studies of sB4, sB2 and sB5 
(biosimilars of etanercept, infliximab and adalimumab) 
were pooled to assess radiographic progression by disease 
activity status.
Methods Patients from each study with radiographic data 
were pooled and grouped based on disease activity state 
(remission, low disease activity (lDa), moderate disease 
activity (MDa) and high disease activity (hDa)), determined 
by disease activity score based on 28- joint count 
(Das28) per erythrocyte sedimentation rate, simplified 
Disease activity index (sDai) and clinical Disease activity 
index (cDai) at different time points. Mean change in 
modified Total sharp score (mTss) and the proportion of 
radiographic non- progressors of higher disease activity 
groups (lDa, MDa and hDa) in reference to remission 
were summarised descriptively, with comparison of Ors 
using logistic models.
Results 1265 patients were included. in all treatments 
combined, the 1 year mean change in mTss was 0.03, 
0.4, 0.3 and 1.3 and proportion of radiographic non- 
progressors was 79.8%, 78.1%, 74.1% and 58.4% in the 
week 24/30 Das28- determined remission, lDa, MDa and 
hDa groups, respectively. Ors (95% cis) of the proportion 
of non- progressors were lowest in the hDa group in 
reference to remission (0.35 (0.23 to 0.54)), followed by 
MDa (0.72 (0.50 to 1.05)) and lDa (0.90 (0.55 to 1.48)) 
groups. similar trends were observed when disease 
activity was assessed using sDai or cDai.
Conclusion a pooled analysis of radiographic assessment 
data from three biosimilar studies showed that 
radiographic progression is small overall but increases 
with worse disease activity.
Trial registration numbers ncT01895309, 
ncT01936181 and ncT02167139
InTROduCTIOn
The structural joint damage and systemic 
complications of rheumatoid arthritis (RA) 
result in a high rate of disability, quality of life 
deterioration and substantial costs to patients 
and society.1–4 Treatment with disease- 
modifying antirheumatic drugs (DMARDs) is 
aimed at achieving low disease activity (LDA) 
or remission in an effort to prevent or mini-
mise joint damage and disability.5 6 Tumour 
necrosis factor (TNF) inhibitors such as 
etanercept, infliximab and adalimumab are 
biological DMARDs (bDMARDs) that are 
indicated and widely used for the treatment 
of patients with RA.7–9 These agents are effec-
tive with respect to reducing disease activity 
and radiographic progression,10–18 the latter 
of which is known to correlate with irre-
versible functional impairment.19 20 A TNF 
inhibitor is appropriate as an initial step- up 
bDMARD therapy in patients exhibiting 
moderate disease activity (MDA) or high 
disease activity (HDA), despite prior therapy 
with methotrexate (MTX) or other conven-
tional synthetic DMARDs.5 6
Key messages
What is already known about this subject?
 ► Tumor necrosis factor (TnF) inhibitors are effec-
tive in reducing disease activity and radiograhpic 
progression
What does this study add?
 ► radiographic progression in patients receiving tu-
mour necrosis factor (TnF) inhibitors was minimal 
overall but increased as disease activity worsens.
 ► One- year mean radiographic progression was high-
est among patients in the high disease activity group 
and lowest among patients in the remission group.
How might this impact on clinical practice?
 ► When treating with TnF inhibitors, the goal should 
be low disease activity or remission at early stages 
of starting therapy.
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The phase III clinical trials of approved biosimilars 
demonstrated non- inferiority in American College of 
Rheumatology (ACR) response rates and comparable 
safety and pharmacokinetics between biosimilars and 
their reference products (etanercept, infliximab and 
adalimumab, respectively).21–26 Analyses of the safety 
and efficacy of switching from etanercept, infliximab 
and adalimumab to their respective biosimilars have 
not identified any issues.25 27–29
Elucidating the relationship between clinical disease 
activity and radiographic progression in patients with 
RA is an area of ongoing interest and research. Indeed, it 
has been known for several decades that disease activity, 
such as swollen joint counts, acute phase reactants or 
levels of composite measures of disease activity (eg, 
disease activity score based on 28- joint count (DAS28), 
Simplified Disease Activity Index (SDAI) or Clinical 
Disease Activity Index (CDAI)), are strongly associated 
with progression of joint damage.7 10 11 30 31 However, it 
has also been noted that bDMARDs may diminish the 
tight link between disease activity and progression even 
at HDA states.32–37 This is due to differences in thresh-
olds that are required to elicit inflammation when 
compared with induction of damage.38 Nevertheless, 
there were some indications that despite the blunting 
of this association, there may still be a relationship 
between disease activity and progression of damage 
even when TNF inhibitors are applied.10 11 To address 
this question in more detail, we herein report a pooled 
analysis of the phase III clinical trials of SB4, SB2 and 
SB5. The objective was to assess 1- year radiographic 
progression by disease activity state at different time 
points in patients who received TNF inhibitors.
MeTHOds
design and patients
Each of the three phase III clinical trials included in this 
pooled analysis had a multicentre, randomised, double- 
blind, parallel- group design and enrolled patients with 
moderately or severely active RA, despite treatment with 
MTX. The methodologies of each of the clinical trials 
have been published in detail elsewhere.21–23 Briefly, 
each study had similar eligibility criteria and, thus, 
similar patient demographics. Patients were between 18 
years and 75 years of age and had been diagnosed with 
RA (per the ACR 1987 revised classification criteria). 
Disease duration was ≥6 months, during which patients 
must have received MTX for ≥6 months and at a stable 
dosage for ≥4 weeks before screening or randomisa-
tion. Additional requirements included the presence 
of active disease, as evidenced by ≥6 swollen joints and 
≥6 tender joints and either erythrocyte sedimentation 
rate (ESR) ≥28 mm/hour or serum C reactive protein 
level ≥1.0 mg/dL, and no prior treatment with biolog-
ical agents.
Given that (1) clinical and radiographic outcomes 
were similar between individual TNF- inhibitor 
biosimilars and their respective reference products and 
(2) no differences regarding clinical and structural 
outcomes are seen between different types of TNF- 
blockers,39 40 we pooled all arms of all three studies 
for the present analyses. Patients were included in this 
pooled analysis if they completed the clinical trial and 
had radiographic data available both at baseline (week 
0) and week 52/54.
data extraction
X- ray data of the left and right hand and left and right 
foot at week 0 and the final assessment at 1 year (ie, 
week 52/54) were used to determine the modified Total 
Sharp Score (mTSS), the sum of the joint erosion and 
joint space narrowing scores.41 42 All X- rays were assessed 
centrally by two independent qualified readers under 
blinded conditions, and the mean scores for the two 
readers were used for this analysis. Radiographic progres-
sion was defined as a mean change in mTSS >0; radio-
graphic non- progressors were defined as patients with a 
mean change in mTSS ≤0. Additionally, the proportion 
of patients with no rapid radiographic progression was 
obtained based on baseline mTSS score (≤5 vs >5). Rapid 
radiographic progression was defined as a 1- year mean 
change in mTSS >1 or>5. At weeks 12, 24 and 52 (SB4/
etanercept and SB5/adalimumab studies) or weeks 14, 
30 and 54 (SB2/infliximab study), disease activity was 
assessed using DAS28 (per ESR), a secondary endpoint 
in each of the three clinical trials, and by post hoc anal-
yses of SDAI and CDAI data. Corresponding Health 
Assessment Questionnaire Disability Index (HAQ- DI), 
Physician Global Assessment Score (PhGA) and Patient 
Global Assessment Score (PGA) were obtained at week 
52/54.
statistical analysis
Patients were pooled and grouped according to disease 
activity state of remission, LDA, MDA and HDA, as 
determined based on DAS28 (ESR), SDAI and CDAI at 
weeks 12/14, 24/30 and 52/54. Remission was defined 
as DAS28 (ESR) <2.6, SDAI ≤3.3 and CDAI ≤2.8. Other 
disease activity cut- off values are presented in online 
supplementary table 1. Analysis of variance (ANOVA) 
testing for a linear trend in 1- year mean change in mTSS 
was used to compare radiographic progression between 
groups. Mean change in mTSS and the proportion of 
radiographic non- progressors of higher disease activity 
groups (LDA, MDA and HDA) in reference to remission 
were summarised descriptively. ORs of the proportion of 
radiographic non- progressors of higher disease activity 
groups (LDA, MDA and HDA) in reference to remission 
were compared using 95% CIs obtained from logistic 
models with disease activity state measurement. The esti-
mated difference of the mean change in mTSS was simi-
larly analysed for the higher disease activity groups (LDA, 
MDA and HDA) in reference to remission. To further 
aid data interpretation, the cumulative proportion of 
patients in different disease activity states at week 24/30 
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Figure 1 One- year radiographic progression in mean change in mTSS based on DAS28 (per erythrocyte sedimentation rate), 
SDAI scores and CDAI scores at week 24/30. CDAI, Clinical Disease Activity Index; DAS28, disease activity score based on 
28- joint count; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease activity; mTSS, modified Total 
Sharp Score; SDAI, Simplified Disease Activity Index. *Estimated difference in reference to remission with p<0.05.
was plotted against the change in mTSS over 1 year in all 
treatment groups.43
An exploratory analysis was done to examine HAQ- 
DI, PhGA and PGA scores at 1 year according to disease 
activity status by DAS28 (ESR), SDAI or CDAI at 6 months.
ResulTs
Of 1580 patients randomised in the three biosim-
ilar trials,21–23 a total of 1265 (80.1%) had an available 
mTSS assessment at baseline and week 52/54 and were 
included in this pooled analysis. Baseline characteristics 
of these patients are summarised in table 1. In all treat-
ments combined, the mean age of participants was 51.3 
years, and most patients were women (81.6%). The mean 
duration of RA was 5.9 years, and the mean mTSS was 
37.1 at baseline. Baseline data for the individual studies 
were published previously.21–23
In all treatments combined, the mean±SD change in 
mTSS from week 0 to the 1 year assessment (week 52/54) 
was 0.4±2.8, and 72.7% of patients (920/1265) were 
radiographic non- progressors.
The following results are based on disease activity 
status at week 24/30. In all treatments combined, 1- year 
mean radiographic progression was highest among 
patients in the HDA group and lowest among patients 
in the remission group, based on DAS28 (ESR), SDAI 
and CDAI (figure 1A–C). The 1- year mean±SD change 
in mTSS was 0.03±2.1 in the remission group, 0.4±2.2 in 
the LDA group, 0.3±2.2 in the MDA group and 1.3±4.4 
in the HDA group, based on DAS28 (ESR), with similar 
results based on SDAI or CDAI (each, p<0.05 by ANOVA 
with linear trend). The estimated difference of the 1- year 
mean change in mTSS in reference to remission, as 
determined by DAS28 (ESR), was significantly larger in 
the HDA group (1.3 (95% CI 0.7 to 1.8); p<0.0001) than 
the MDA group (0.2 (95% CI −0.3 to 0.7); p=0.5047) or 
LDA group (0.4 (95% CI −0.3 to 1.0); p=0.4455).
The corresponding proportions of radiographic 
non- progressors were 79.8% (182/228) in the remis-
sion group, 78.1% (125/160) in the LDA group, 74.1% 
(473/638) in the MDA group and 58.4% (139/238) in 
the HDA group, based on DAS28 (ESR), with similar 
results observed based on SDAI and CDAI (figure 2A–C). 
The number of patients in each disease activity measure 
was highest in the MDA group by DAS28, SDAI and CDAI 
at both weeks 12/14 and 24/30. The number in the 
remission group increased whereas the number in the 
HDA group decreased from week 12/14 to week 24/30 
(online supplementary table 2).
The proportion of patients with no rapid radiographic 
progression (change in mTSS at 1 year ≤5) at 1 year was 
higher (96.1%, 1215/1264) compared with the propor-
tion of patients (83.9%, 1060/1264) with change in 
mTSS at 1 year ≤1. When stratified by baseline mTSS 
score ≤5 or>5, the proportion of patients with no rapid 
radiographic progression tended to increase with lower 
baseline mTSS score and with better disease activity status 
by DAS28 at week 24/30 (online supplementary table 3). 
Mean change in mTSS at 1 year, when stratified by base-
line mTSS score, was higher with greater baseline mTSS 
score (>5) compared with the lower baseline mTSS score 
(≤5) (online supplementary table 3).
When evaluating 1- year radiographic progression 
based on DAS28 (ESR) at week 24/30 and in reference to 
remission, in all treatments combined, the OR (95% CI) 
of the proportion of radiographic non- progressors was 
lowest in the HDA group (0.35 (0.23 to 0.54); p<0.0001), 
followed by the MDA (0.72 (0.50 to 1.05); p=0.0860) and 
LDA (0.90 (0.55 to 1.48); p=0.6851) groups (figure 3A). 
Similar results were obtained based on DAS28 at week 
12/14 in all treatments combined group (figure 3B). 
Results in different combinations of treatment groups 
were generally consistent based on DAS28 at week 24/30 
(online supplementary figure 1A) and at week 12/14 
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Figure 2 Proportion of radiographic progressors and non- progressors based on DAS28 (per erythrocyte sedimentation rate), 
SDAI scores and CDAI scores at week 24/30. CDAI, Clinical Disease Activity Index; DAS28, disease activity score based on 
28- joint count; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease activity; SDAI, Simplified Disease 
Activity Index.
Figure 3 ORs of radiographic non- progressors in reference to remission by disease activity score based on 28- joint count 
(per erythrocyte sedimentation rate) at (A) week 24/30 and (B) week 12/14 in all treatments combined group. DAS, disease 
activity score; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease activity.
(online supplementary figure 1B) with those described 
above for all treatments combined group. Cumulative 
probability plots of 1- year radiographic progression 
showed that many patients in the MDA and HDA groups 
by DAS28, SDAI and CDAI still had a high progression 
rate (figure 4A–C).
In terms of the OR (95% CI) of the proportion of radio-
graphic non- progressors, the similar trend was shown for 
SDAI and CDAI at week 24/30 (supplementary figure 
2A) and at week 12/14 (online supplementary figure 
2B); although for SDAI and CDAI, the OR was significant 
when comparing both HDA and MDA with remission at 
week 12/14 and week 24/30, not HDA alone as based on 
DAS28 at week 24/30.
As an exploratory analysis, HAQ- DI, PhGA, PGA scores 
at week 52/54 were obtained according to the disease 
activity status at week 24/30 and scores increased as 
disease activity worsened (online supplementary table 4).
dIsCussIOn
This pooled analysis demonstrated that disease activity 
correlates with radiographic progression even in 
anti- TNF- treated patients. These observations were 
evident regardless of how disease activity was evaluated 
(DAS28 (ESR), SDAI or CDAI) and across the multiple 
treatment groups that were assessed.
In general, it has been reported that treatment with 
TNF inhibitors or other bDMARDs inhibits the progres-
sion of joint damage.10–18 The results of our study show 
that even with TNF inhibitor therapy, the progression 
of joint damage is only arrested when patients achieve 
remission. Consistent with the treat- to- target recommen-
dations,5 6 44 our findings suggest that LDA is, indeed, 
closely related to remission since progression of joint 
damage was not significantly different in patients with 
LDA versus those in remission, whereas significantly 
greater progression was observed in patients with MDA 
or HDA after 6 months of TNF inhibitor therapy. In 
CDAI and SDAI remission, progression rates were signifi-
cantly lower compared with MDA and HDA, supporting 
the stringency of this remission cut- point.45
Thus, our findings support the importance of a treat- 
to- target approach; that is, when the treatment target of 
LDA (especially when using CDAI or SDAI) is not met 
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Figure 4 Cumulative probability plot of 1- year radiographic progression based on (A) DAS using 28- joint count (per 
erythrocyte sedimentation rate), (B) SDAI scores and (C) CDAI scores. CDAI, Clinical Disease Activity Index; DAS, disease 
activity score; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease activity; mTSS, modified Total 
Sharp Score; SDAI, Simplified Disease Activity Index.
between weeks 12 and 24, advancing to the next line of 
therapy is recommended.4–6 44
Increased disease activity at baseline is also associ-
ated with disease activity at 6 months and radiographic 
progression. This was shown by the ASPIRE, OPTIMA and 
PREMIER post hoc analysis, which revealed that baseline 
disease activity by composite measures was the strongest 
predictor of insufficient response to MTX and radio-
graphic progression at 6 months as well as at 1 year.10 46 47 
Taken together with our results, it is suggested that a 
significant portion of the progression occurs in the first 
few months, and baseline disease activity plays a role in 
clinical and radiographic response.
An exploratory analysis showed that disease activity is 
associated with radiographic progression and with patient 
functional outcomes and PhGA. This again confirms the 
importance of treat- to- target approach.
At the individual level, some patients may still have large 
extents of progression, up to 30 mTSS points in HDA. 
This finding has also been seen in other studies with 
bDMARDs examining the association of radiographic 
progression and disease activity states. Patients with HDA 
levels had less radiographic progression if treated with 
TNF inhibitors compared with MTX alone.11 33–35
Our study has some limitations. First, there were differ-
ences between studies in disease duration and baseline 
mTSS. Baseline mTSS scores are known to correlate with 
radiographic progression,48 while disease duration has 
been observed to be associated with total radiographic 
score.49 However, since the populations were pooled, this 
allowed inclusion of a broader range of baseline data.
In terms of radiographic evaluation, X- rays of each 
study were read centrally. Originally, these studies were 
not designed to be combined, and the readers and 
centres differed by product. However, X- rays were all 
read by qualified readers, and obtaining the mean from 
these two qualified readers reduces some of the inter- 
reader variability between the studies. Indeed, the fact 
that progression was low across all types of TNF inhibitors 
is in line with the low progression seen in the previously 
studies of each originator product11 34 35 37 and further 
supports the validity of the presents results.
Differences in radiographic progression by product 
or between biosimilars and reference products were 
not explored, but there were similar progression rates 
for reference products and biosimilars in all originating 
studies.21–23 Additional limitations that may confound 
interpretation of our findings include the lack of a 
placebo group. Although the overall study designs and 
baseline patient characteristics were similar across the 
three phase III clinical trials, they were not designed with 
a combined analysis in mind.
In conclusion, our pooled radiographic assessment 
data from three different phase III TNF inhibitor clinical 
trials of biosimilar versus reference products showed that 
radiographic progression is minimal overall but increases 
as disease activity worsens, despite using TNF inhibitors. 
Thus, in line with the treat- to- target recommendations, 
MDA or HDA are unacceptable states when treating 
patients with TNF inhibitors, even from the standpoint 
of radiographic progression of joint damage.
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